WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Sponsor
Alcon Research
Study ID
NCT00992563
Phase
PHASE2
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.

Key Dates

First listed
Oct 9, 2009
Start date
Jun 30, 2010
Status verified
Jul 2014
Primary completion
May 31, 2011
Completion
May 31, 2011

Study Design

Enrollment
35 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AL-39324 Concentration Level A
    AL-39324 ophthalmic suspension, single intravitreal injection
  • Experimental: AL-39324 Concentration Level B
    AL-39324 ophthalmic suspension, single intravitreal injection
  • Experimental: AL-39324 Concentration Level C
    AL-39324 ophthalmic suspension, single intravitreal injection
  • Experimental: AL-39324 Concentration Level D
    AL-39324 ophthalmic suspension, single intravitreal injection
  • Experimental: AL-39324 Concentration Level E
    AL-39324 ophthalmic suspension, single intravitreal injection
  • Active Comparator: Lucentis
    Ranibizumab 10 mg/mL solution, single intravitreal injection

Primary Outcome Measure

Incidence of targeted adverse events occurring in the study eye [ Time Frame: Up to Day 7 after injection ]

Related Studies